Can IP Waivers Resolve Vaccine Inequity?
Dr. Lindsay Newman, Director of Economics & Country Risk, IHS Markit
11-May-21 07:30

Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
With glaring inequities in the supply and distribution of vaccines, the Biden administration has backed a plan to waive intellectual property rights for Covid-19 vaccines and treatments. We speak to Dr. Lindsay Newman, Director of Economics & Country Risk from IHS Markit on whether this could provide a solution to help end the pandemic.
Image Credit: Shutterstock.com
Produced by: Shazana Mokhtar
Presented by: Khoo Hsu Chuang, Philip See
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Business Analysis, Trends and Forecasts, Markets, Politics, law & legal matters, Health Policy, Diseases & Conditions, Mental Health, Healthy Living, Fitness, Science, Investments
Tags: vaccine, intellectual property, waiver, pandemic,